Industry News (HBV Therapies)

Data Presented on Drug Effective Against Resistant HBV

Published in Hepatitis Weekly, April 26th, 1999

Gilead Sciences, Inc. announced the first clinical data demonstrating that its investigational compound adefovir dipivoxil has potent antiviral activity in patients with chronic hepatitis B virus (HBV) infection who have failed antiviral therapy with lamivudine due to the development of resistance mutations.

These in vivo data support earlier laboratory results indicating that adefovir remains active against lamivudine-resistant HBV, the company says.

"HBV resistance to lamivudine occurs in 14 to 30 percent of patients with chronic HBV who have been treated for one year and becomes even more common after 24 months of therapy," said clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (1999-04-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry